Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)

NCT01478269 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT01478269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01478269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Observational
Overall status
Completed
Start date
May 31, 2009
Completion date
May 31, 2011
Enrollment
1,927 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphomas